X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): JR-141
Therapeutic Area: Genetic Disease Product Name: JR-141
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021
Details:
JR-141 is a recombinant fusion protein of antibody against the human transferrin receptor and idursulfase, the enzyme missing or malfunctioning in subjects with MPS II.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): JR-141
Therapeutic Area: Genetic Disease Product Name: JR-141
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021
Details:
In this study, 50 patients with Hunter syndrome will be treated with JR-141 or the standard treatment for up to 105 weeks under a standard of care controlled, parallel-group trial design.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): JR-141
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2020
Details:
The presentations highlight two candidates from JCR’s development pipeline for lysosomal storage disorders; JR-141 and JR-162.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
